Levofloxacin pharmacokinetics and serum bactericidal activities against five enterobacterial species
- PMID: 11083664
- PMCID: PMC90229
- DOI: 10.1128/AAC.44.12.3478-3480.2000
Levofloxacin pharmacokinetics and serum bactericidal activities against five enterobacterial species
Abstract
After oral administration of 500 mg of levofloxacin to 12 volunteers, we investigated the pharmacokinetics and serum bactericidal activities (SBAs) against five strains of members of the family Enterobacteriaceae. Pharmacokinetic data were as follows: maximum concentration in serum, 6.36 +/- 0.57 mg/liter; area under the concentration-time curve, 43.6 +/- 6.23 mg. h/liter; elimination half-life 4.23 +/- 0.87 h. SBAs were present for 24 h against Escherichia coli and Citrobacter freundii. The SBAs at 1, 12, and 24 h after administration against E. coli were 1:108, 1:29, and 1:7, respectively, and those against Citrobacter freundii were 1:74, 1:25, and 1:7, respectively. The SBAs were present for 12 h against the other three organisms tested. The SBAs against Serratia marcescens were 1:28 and 1:9 at 1 and 12 h, respectively; the SBAs against Klebsiella pneumoniae were 1:25 and 1:7 at 1 and 12 h, respectively; and the SBAs against Enterobacter cloacae were 1:24 and 1:10 at 1 and 12 h, respectively.
References
-
- Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother. 1997;40:639–651. - PubMed
-
- Craig W A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing in mice and men. Clin Infect Dis. 1998;26:1–12. - PubMed
-
- Davis R, Bryson H M. Levofloxacin—a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs. 1994;47:677–700. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
